{
    "id": 2954,
    "fullName": "TP63 inact mut",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "TP63 inact mut indicates that this variant results in a loss of function of the TP63 protein. However, the specific amino acid change has not been identified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 8626,
        "geneSymbol": "TP63",
        "terms": [
            "TP63",
            "AIS",
            "B(p51A)",
            "B(p51B)",
            "EEC3",
            "KET",
            "LMS",
            "NBP",
            "OFC8",
            "p40",
            "p51",
            "p53CP",
            "p63",
            "p73H",
            "p73L",
            "RHS",
            "SHFM4",
            "TP53CP",
            "TP53L",
            "TP73L"
        ]
    },
    "variant": "inact mut",
    "createDate": "01/19/2015",
    "updateDate": "10/07/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1622,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, APR-246 (PRIMA1-MET) treatment of Tp53-null lung adenocarcinoma cells expressing mutant Tp63 resulted in Tp63-dependent increase in apoptosis, increased Tp63 target gene expression, and redistribution of Tp63 in cell culture (PMID: 20818419).",
            "molecularProfile": {
                "id": 2779,
                "profileName": "TP53 loss TP63 inact mut"
            },
            "therapy": {
                "id": 1946,
                "therapyName": "APR-246",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1743,
                    "pubMedId": 20818419,
                    "title": "PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20818419"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2778,
            "profileName": "TP63 inact mut",
            "profileTreatmentApproaches": [
                {
                    "id": 5849,
                    "name": "p53 Activator",
                    "profileName": "TP63 inact mut"
                }
            ]
        },
        {
            "id": 2779,
            "profileName": "TP53 loss TP63 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}